Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 29 citing articles:

Cytotoxic Activity of Herbal Medicines as Assessed in Vitro: A Review
Shahin Gavanji, Azizollah Bakhtari, Ademola C. Famurewa, et al.
Chemistry & Biodiversity (2023) Vol. 20, Iss. 2
Open Access | Times Cited: 24
Strategic and Technical Considerations in Manufacturing Viral Vector Vaccines for the Biomedical Advanced Research and Development Authority Threats
Lindsay A. Parish, Shyam Rele, Kimberly A. Hofmeyer, et al.
Vaccines (2025) Vol. 13, Iss. 1, pp. 73-73
Open Access
Advances in the design and delivery of RNA vaccines for infectious diseases
Abhijeet Lokras, Thomas Rønnemoes Bobak, Saahil Baghel, et al.
Advanced Drug Delivery Reviews (2024) Vol. 213, pp. 115419-115419
Open Access | Times Cited: 5
Vaccine process technology—A decade of progress
Barry C. Buckland, Gautam Sanyal, Todd Ranheim, et al.
Biotechnology and Bioengineering (2024) Vol. 121, Iss. 9, pp. 2604-2635
Open Access | Times Cited: 4
The Platform Technology Approach to mRNA Product Development and Regulation
John Howard SKERRITT, Carolyn Tucek-Szabo, Brett Sutton, et al.
(2024)
Open Access | Times Cited: 3
The Platform Technology Approach to mRNA Product Development and Regulation
John Howard SKERRITT, Carolyn Tucek-Szabo, Brett Sutton, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 528-528
Open Access | Times Cited: 3
Cytokines as fast indicator of infectious virus titer during process development
Johanna Bacher, Narges Lali, Florian Steiner, et al.
Journal of Biotechnology (2024) Vol. 383, pp. 55-63
Open Access | Times Cited: 2
Correlating Stability-Indicating Biochemical and Biophysical Characteristics with In Vitro Cell Potency in mRNA LNP Vaccine
Xin Tong, Jessica Raffaele, Katrina Feller, et al.
Vaccines (2024) Vol. 12, Iss. 2, pp. 169-169
Open Access | Times Cited: 2
Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays
Xuanxuan Zhang, Xing Wu, Qian He, et al.
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 270-277
Open Access | Times Cited: 7
Development and application of potency assays based on genetically modified cells for biological products
Lei Yu, Yong Zhou, Junzhi Wang
Journal of Pharmaceutical and Biomedical Analysis (2023) Vol. 230, pp. 115397-115397
Closed Access | Times Cited: 7
An Update on Resurgence of Diphtheria Cases in West Africa: Investigating Factors Behind Outbreaks Despite Annual WHO Vaccination Initiatives
Levi Tuwleh, Javeria Hamraa, Ali Hassan, et al.
(2024)
Open Access | Times Cited: 1
Lymphatic Endothelial Cells Produce Chemokines in Response to the Lipid Nanoparticles Used in RNA Vaccines
Yi Liu, Miho Suzuoki, Hiroki Tanaka, et al.
Biological and Pharmaceutical Bulletin (2024) Vol. 47, Iss. 3, pp. 698-707
Open Access | Times Cited: 1
Evolution of Vaccines Formulation to Tackle the Challenge of Anti-Microbial Resistant Pathogens
Francesco Tognetti, Massimiliano Biagini, Maxime Denis, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12054-12054
Open Access | Times Cited: 2
Fully automated high-throughput immuno-µPlaque assay for live-attenuated tetravalent dengue vaccine development
Yi Wang, Matthew C. Troutman, Carl Hofmann, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine
Rosa Bartolomeo, Fulvia Troise, Simona Allocca, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 325-325
Open Access
Effects of Shock and Vibration on Product Quality during Last-Mile Transportation of Ebola Vaccine under Refrigerated Conditions1
Linda Bus-Jacobs, Rute Lau, Marjolein Soethoudt, et al.
Emerging infectious diseases (2024) Vol. 30, Iss. 4
Open Access
Expression system and purification process for the vaccine production
Suneetha Vuppu, Toshika Mishra, Amol D. Gholap, et al.
Elsevier eBooks (2024), pp. 131-151
Closed Access
Analytical Performance of a Multiplexed Microarray Assay for Rapid Identity and Quantification of a Multivalent Mrna Vaccine
Megan N. Gerold, Evan Toth, Rebecca H. Blair, et al.
(2024)
Closed Access
Development of a Cell-Based Reporter Potency Assay for Live Virus Vaccines
Dengyun Sun, Brian K. Meyer, Dhanvanthri S. Deevi, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 769-769
Open Access
Development of subunit vaccine: A step forward toward cost-effective technology of vaccine candidate discovery
Maaz Waseem, Hurria Qureshi, Kashaf Maheen, et al.
Elsevier eBooks (2024), pp. 41-60
Closed Access
Analytical Performance of a Multiplexed Microarray Assay for Rapid Identification and Quantification of a Multivalent mRNA Vaccine
Megan N. Gerold, Evan Toth, Rebecca H. Blair, et al.
Vaccines (2024) Vol. 12, Iss. 10, pp. 1144-1144
Open Access
Development of an ELISA for an effective potency determination of recombinant rabies human monoclonal antibody
Ambika Divase, Sambhaji Pisal, Manjusha Dake, et al.
Journal of Immunological Methods (2024), pp. 113769-113769
Closed Access
Analytical procedure life-cycle management
Gerald Gellermann, Cristiana Campa, Thomas Pohl, et al.
Elsevier eBooks (2024), pp. 127-140
Closed Access
Development and validation of a VP7-specific EIA for determining the potency and stability of inactivated rotavirus vaccine
Sung‐Sil Moon, Houping Wang, Kimberly Brown, et al.
Journal of Virological Methods (2024) Vol. 332, pp. 115079-115079
Closed Access
Steps toward nebulization in-use studies to understand the stability of new biological entities
Carlos Victor Montefusco-Pereira
Drug Discovery Today (2022) Vol. 28, Iss. 2, pp. 103461-103461
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top